Workflow
鱼跃医疗(002223) - 002223鱼跃医疗投资者关系管理信息20250516
YUYUE MEDICALYUYUE MEDICAL(SZ:002223)2025-05-18 13:50

Group 1: Company Strategic Direction - The company's future strategic direction focuses on three main areas: globalization, digitalization, and wearability [1] - The company aims to enhance overseas market presence by strengthening talent allocation and cultural synergy in key regions [1] - The integration of AI technology with medical devices is a priority, aiming to provide competitive products and comprehensive health management solutions [1] Group 2: Overseas Market Strategy - The company has rapidly developed its overseas sales, exemplified by the establishment of a subsidiary in Thailand in 2021 [2] - Future plans include replicating the Thailand model in other regions while adapting to local cultural characteristics [2] Group 3: AI Technology Application - The company views AI as a key factor for industry transformation and is integrating it into operations and product development [3] - AI technology is being utilized in various aspects, including algorithm innovation for CGM products and support for operational management [3] Group 4: Product Development and Competitive Advantages - The Anytime5 series glucose monitoring system features significant advantages such as enhanced accuracy and a maximum usage time of 16 days [4] - New product development will focus on global, digital, and wearable strategies, particularly in respiratory and continuous monitoring products [5] Group 5: R&D Investment and Planning - The company emphasizes the importance of R&D talent and plans to increase investment in AI-related business, product design, and new product registration [7] - R&D expenses will be aligned with business development needs while maintaining reasonable levels [7] Group 6: Emergency Business Development - The emergency business is entering a phase of rapid growth, focusing on a combined development model of "overseas + China" [9] - Product strategy will target public emergency solutions, new generation in-hospital defibrillation products, and pre-hospital emergency product lines [9]